The company’s new Sugar Land, TX distribution facility is the second for Quva, as it expands its 503B forward distribution capabilities and adds another 20,000 sq. ft. of distribution capacity.
The forward distribution facilities complement Quva’s integrated services platform and are designed to redefine service expectations and create greater resiliency and reliability for Quva’s health system and hospital customers.
SUGAR LAND, Texas, May 14, 2025 /PRNewswire/ — QuVa Pharma, Inc. (“Quva”) announced today that it has added another forward distribution center to its existing 503B sterile injectable compounded medications platform. Quva now has two dedicated forward distribution facilities, with the new 20,000 sq. ft. distribution facility in Sugar Land, TX providing additional overall capacity beyond that offered by the company’s existing 40,000 sq. ft. distribution facility in Phoenix, AZ.
Located in close proximity to Quva’s Sugar Land, TX manufacturing operations, this new forward distribution center was designed to meet the growing demand for secure, efficient, and compliant product handling and shipping. It enhances the company’s supply chain capabilities with cutting-edge infrastructure that supports cold chain and DEA regulatory compliance. This new facility represents a major investment in operational excellence and regulatory compliance and further increases capacity in Quva’s production facilities. Furthermore, this distribution facility will be co-located with Quva’s new, state-of-the-art IV bag production operations that will implement automated processes that improve bag operations from end-to-end manufacturing—this is scheduled to be operational in the second half of 2026 and increase Quva’s overall production capacity to three facilities and over 260,000 sq.ft. across its network.
“Quva is building a new future of reliability and transparency for our industry. This newest distribution center is progress in our mission to provide high quality and effective medications and services to facilitate efficient and accurate delivery of patient care,” said Stuart Hinchen, Quva co-founder and CEO. “We understand hospitals’ need for the right drug at the right time and in the right quantities, and with uncertainties like tariffs and DSCSA implementation being front and center for our customers, this added capability to increase access and reliability is critical to help meet those expectations.”
About Quva
Quva is a national, industry-leading provider of health-system pharmacy services and solutions, including 503B sterile injectable outsourcing and data software solutions that generate insights to help power the business of pharmacy.
The company’s Quva Pharma solutions are offered by its FDA-registered 503B outsourcing facilities, which provide hospitals with essential medications in ready-to-administer formats that are critical to effective patient care. Based upon Quva’s cGMP and pharmaceutical manufacturing expertise, broad sterile-to-sterile product portfolio, expansive capacity across multiple production facilities leveraging automation and integrated technologies, dedicated forward distribution capabilities, transparent and accountable customer service, and a patient-first safety orientation, its Quva Pharma solutions help hospitals better meet their patient care and operational needs while reducing compliance risk.
The company’s Quva BrightStream predictive analytics and data insights software solutions provide health systems with the ability to aggregate, normalize, and analyze large amounts of complex data across sites of care. Through a proprietary machine learning and AI platform, complex data is transformed into actionable insights supporting revenue optimization, script capture, inventory management, drug shortage control, and more, enabling health-system pharmacies the clarity to make better decisions.
Quva’s overall progressive and integrated platform helps health-systems transform pharmacy management to achieve greater value by operating more efficiently and effectively in delivering high-quality patient care.
For more information, please visit www.quvapharma.com or follow Quva on LinkedIn at https://www.linkedin.com/company/quvapharma-inc-/.
SOURCE QuVa Pharma, Inc.